Lantern Pharma Inc.

4.14 USD
+0.23 (+5.88%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lantern Pharma Inc. stock is down -33.01% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 4 June’s closed higher than May.

About Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company was incorporated in 2013 and is headquartered in Dallas, Texas.